Targeting Liver Metastases in Uveal Melanoma: ATX-LPA Mediated Immunosuppression and Novel Therapeutic Approaches - Top-Institutions - MDSpire

Targeting Liver Metastases in Uveal Melanoma: ATX-LPA Mediated Immunosuppression and Novel Therapeutic Approaches

  • By

  • A. Turner, Jacqueline

  • D'Antonio, Marc

  • Montane, Heather

  • MacBeth, Morgan

  • Katsnelson, Elizabeth

  • Robinson, William

  • Tobin, Richard

  • Couts, Kasey L.

  • Markovic, Svetomir N

  • Torres, Raul M

  • May 29, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Leiden University Medical Centre
    Leiden University Medical Centre

    Leiden, Netherlands

    Key Differentiators

    • Oncology

  • #2

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, Ohio

    Key Differentiators

    • Oncology

  • #3

    Rutgers Cancer Institute of New Jersey
    Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

    Key Differentiators

    • Oncology

  • #4

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #5

    Vanderbilt University
    Vanderbilt University

    Nashville, Tennessee

    Key Differentiators

    • Oncology

Original Source(s)

Targeting Liver Metastases in Uveal Melanoma: ATX-LPA Mediated Immunosuppression and Novel Therapeutic Approaches

  • by A. Turner, Jacqueline , D'Antonio, Marc , Montane, Heather , MacBeth, Morgan , Katsnelson, Elizabeth , Robinson, William , Tobin, Richard , Couts, Kasey L., Markovic, Svetomir N, Torres, Raul M

  • May 29, 2026

Related Content

Epidemiology and Treatment Patterns of Stage III Resectable Melanoma Treated with Adjuvant Therapy: A Real-World Study Using the SNDS Database in France

Ultraviolet radiation as a double-edged regulator of melanocyte function in vitiligo therapy and melanoma carcinogenesis

Intercellular mitochondrial transfer in melanoma progression and therapeutic resistance: mechanisms and targeting potential